Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

J-Valve Transfemoral Pivotal Study

NCT: NCT06455787 · RECRUITING

NCT IDNCT06455787
StatusRECRUITING
Start Date2024-10-17
Completion2032-02

Brief Summary

The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR). A Cardiac Magnetic Resonance (CMR) sub-study will examine if intervention for AR translates to improved ventricular remodeling, the impact of LV remodeling on clinical outcomes and quality of life, as well as volumetric and myocardial differences between genders.

Frequently Asked Questions

What is J-Valve Transfemoral Pivotal Study?

J-Valve Transfemoral Pivotal Study is a clinical trial registered under NCT06455787. Current status: RECRUITING.

What is the status of NCT06455787?

The current status of NCT06455787 (J-Valve Transfemoral Pivotal Study) is: RECRUITING.

When did J-Valve Transfemoral Pivotal Study start?

J-Valve Transfemoral Pivotal Study started on 2024-10-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.